<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974686</url>
  </required_header>
  <id_info>
    <org_study_id>201603167</org_study_id>
    <secondary_id>CRAD001AUS209T</secondary_id>
    <nct_id>NCT02974686</nct_id>
  </id_info>
  <brief_title>Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation</brief_title>
  <official_title>Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on&#xD;
      triple maintenance immunosuppression, which means that patients take 3 types of&#xD;
      immunosuppression drugs to suppress their immune system including tacrolimus, mycophenolate&#xD;
      (MPA), and prednisone. However, due to the effects of MPA on the gastrointestinal tract,&#xD;
      patients often complain of GI adverse effects. Current practice is to either dose-reduce MPA&#xD;
      or convert the patient to an alternative agent, typically Azathioprine. Both of these&#xD;
      strategies have limitations, largely due to concerns related to efficacy. Everolimus (EVR)&#xD;
      has demonstrated similar efficacy to MPA in renal transplantation and may offer a benefit&#xD;
      related to GI adverse effects, so the investigators will convert patients to EVR in this&#xD;
      study. Patients who are within their first year post-transplant will be converted to EVR upon&#xD;
      enrollment in the study, and serial measurements ,or a series of measurements looking for an&#xD;
      increase or decrease over time, of GI adverse effects will be conducted over 1 year&#xD;
      post-enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>1, 6, and 12 months</time_frame>
    <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Proven Acute Rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Gastrointestinal Disorder, Functional</condition>
  <arm_group>
    <arm_group_label>Interventional (EVR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Agent (MPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will have baseline data collected while on MPA for comparison with EVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Interventional (EVR)</arm_group_label>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid</intervention_name>
    <arm_group_label>Prior Agent (MPA)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Kidney transplant recipients at Washington University/Barnes-Jewish Hospital&#xD;
&#xD;
          2. Experiencing GI toxicity from MPA as determined by the treating physician within 12&#xD;
             months post-renal transplant&#xD;
&#xD;
          3. On standard immunosuppression with tacrolimus and prednisone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dual organ or kidney after another solid organ transplant&#xD;
&#xD;
          2. Presence of a preexisting significant GI condition that does not have a presumed&#xD;
             causal relationship with MPA&#xD;
&#xD;
          3. Evidence of any GI disorder induced by an infection, underlying medical condition, or&#xD;
             concomitant medication other than MPA&#xD;
&#xD;
          4. Estimated glomerular filtration rate (eGFR) &lt;40 ml/min at time of possible conversion&#xD;
&#xD;
          5. Proteinuria &gt;1 gram/day at time of possible conversion&#xD;
&#xD;
          6. Profound bone marrow suppression at the time of possible conversion as defined as:&#xD;
&#xD;
               -  Hemoglobin &lt;10 g/dL&#xD;
&#xD;
               -  White blood cell (WBC) &lt; 3 K/cumm&#xD;
&#xD;
               -  Platelets &lt;100 K/cumm&#xD;
&#xD;
          7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound&#xD;
             infection, incisional hernia, lymphocele, seroma)&#xD;
&#xD;
          8. Elevated total cholesterol (&gt;350 mg/dL) and/or triglycerides (&gt;500 ng/dL) at time of&#xD;
             possible conversion&#xD;
&#xD;
          9. Hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <results_first_submitted>June 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02974686/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interventional Everolimus (EVR)</title>
          <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
        </group>
        <group group_id="P2">
          <title>Prior Agent Mycophenolic Acid (MPA)</title>
          <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</population>
      <group_list>
        <group group_id="B1">
          <title>Interventional (EVR)</title>
          <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
        </group>
        <group group_id="B2">
          <title>Prior Agent (MPA)</title>
          <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Symptom Rating Scale</title>
        <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
        <time_frame>3 months</time_frame>
        <population>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional (EVR)</title>
            <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
          </group>
          <group group_id="O2">
            <title>Prior Agent (MPA)</title>
            <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptom Rating Scale</title>
          <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
          <population>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Symptom Rating Scale</title>
        <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
        <time_frame>1, 6, and 12 months</time_frame>
        <population>Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional (EVR)</title>
            <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
          </group>
          <group group_id="O2">
            <title>Prior Agent (MPA)</title>
            <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptom Rating Scale</title>
          <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
          <population>Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Proven Acute Rejection</title>
        <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
        <time_frame>12 months</time_frame>
        <population>Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional Everolimus (EVR)</title>
            <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
          </group>
          <group group_id="O2">
            <title>Prior Agent Mycophenolic Acid (MPA)</title>
            <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy Proven Acute Rejection</title>
          <description>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</description>
          <population>Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</time_frame>
      <desc>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Interventional (EVR)</title>
          <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus&#xD;
Everolimus</description>
        </group>
        <group group_id="E2">
          <title>Prior Agent (MPA)</title>
          <description>Patient will have baseline data collected while on MPA for comparison with EVR&#xD;
Mycophenolic Acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. R. Delos Santos</name_or_title>
      <organization>Washington University</organization>
      <phone>314-362-8351</phone>
      <email>delossantos@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

